Background: Antibiotic treatment is a well-known risk factor for healthcare facility-associated Clostridioides (Clostridium) difficile infection (HCF-CDI). Antibiotic stewardship programmes (ASPs) targeting high-risk antibiotics have been shown to decrease HCF-CDI incidence. HCF-CDI incidence is high in Nordic countries despite relatively low antibiotic use in hospital.
Introduction
Clostridium difficile (recently reclassified as Clostridioides difficile, 1 although this has yet to be fully adopted 2 ) is a Gram-positive endospore-forming bacterium causing gastrointestinal infections. Healthcare facility-associated C. difficile infections (HCF-CDI) account for the majority of CDI cases 1, 2 and are among the most common healthcare-related infections overall. 3 Apart from hospital stay, the main risk factors for acquiring HCF-CDI are antibiotic use, advanced age and multiple comorbidities. 4, 5 Clindamycin and second-and third-generation cephalosporins are the antibiotics most prone to cause HCF-CDI. 6 Thus, one would expect a low incidence of HCF-CDI in countries where the use of antibiotics is low, particularly when there is also low use of antibiotics associated with a high risk of HCF-CDI. The incidence of HCF-CDI in the Nordic countries, however, appears to be among the highest in Europe 7 despite comparatively low consumption of antibiotics and low levels of antimicrobial resistance. 8 The reverse has been noted in India, where antibiotic use is unregulated and antimicrobial resistance is widespread, but CDI incidence seems to remain moderate or low. 9 This apparent paradox may partly be explained by underdiagnosis in countries with high antibiotic use. 7 However, a clear-cut relationship between cephalosporin consumption and CDI incidence within a country has been questioned. 10 Antibiotic stewardship programmes (ASPs) limiting the use of cephalosporins and other broad-spectrum antibiotics have been shown in several studies to lower HCF-CDI incidence rates. [11] [12] [13] [14] To our knowledge, no previous study using such an ASP has been conducted in a setting with low antibiotic use and antimicrobial resistance, but with high HCF-CDI incidence.
The aim of the study was to determine the effects of a hospital ASP restricting cephalosporin use on the HCF-CDI incidence in the setting described. A nearby hospital of comparable size and function, where no ASP was implemented, served as a control.
Patients and methods

Ethics approval
The study was approved by the regional ethics review board at the University of Gothenburg, Sweden (reference number: 227-16). Informed consent was waived because of the retrospective observational nature of the study.
Setting and design
This was a two-centre observational study at secondary care hospitals in the same administrative region in western Sweden, one where an ASP was implemented and one where no ASP was implemented: Södra Ä lvsborg Hospital (henceforth referred to as the ASP hospital) with 550 beds, and Skaraborg Hospital (referred to as the non-ASP hospital) with 617 beds. We conducted a retrospective chart review of all patients with HCF-CDI during the years 2007, 2012 and 2015 at both hospitals. Management of HCF-CDI was similar in both hospitals for all years. First-line treatment was oral metronidazole, 400 mg %3 for 10 days, with oral vancomycin 125 mg %4 for 10 days as the main alternative. Guidelines for preventing crossinfection included isolation of symptomatic patients, hand-washing with soap before disinfection for healthcare workers attending the patient and disinfection of near-patient surfaces with peroxygenic acid (Virkon V R ) or alcohol-based disinfectants. Sodium hypochlorite-based disinfectants are sparsely used in Sweden for environmental reasons, and were not used at any of the hospitals any year. There were no recognized outbreaks of HCF-CDI in the study periods.
Intervention
The ASP, initiated in 2008, included interventions such as new guidelines for antibiotic use without cephalosporins, an IT-based tool for registering the cause of prescription for all antibiotics, assigned staff for strategic work, coordination with the hospital's infection control unit and education of hospital staff. Hospital-wide use of cephalosporins decreased by 86% from before the programme started to the time when it was fully implemented in December 2010.
Case definition
Patients demonstrating a positive test for C. difficile toxins A or B were included in the study. As samples were collected clinically, diarrhoea or other characteristic symptoms of CDI were assumed present in cases in which this was not explicitly mentioned in the medical records. Two different enzyme immunoassay (EIA) tests were used in the study. At the ASP hospital, Premier V R A&B (Meridian Bioscience, Charlotte, NC, USA) was used in 2007 and Vidas V R A&B (bioMérieux, Marcy-l'Étoile, France) was used in 2012 and 2015. The former test returns either positive or negative results, whereas the latter also includes equivocal results, whereupon a new test is advised if symptoms persist. Equivocal results excluded, comparisons of the Premier test and Vidas test have shown similar sensitivity and specificity. 15 However, a local validation study (A. Edberg, personal communication) indicated that, among Vidas test equivocal results, the majority would have returned positive results with the Premier test. For this reason, we reviewed the charts of patients with equivocal test results and included them if they were treated for clinically suspected HCF-CDI or had diarrhoea that did not spontaneously resolve and was not explained by other diagnoses. At the non-ASP hospital, the Premier test was used in 2007 and 2012 and formed the basis for inclusion in the study as described above. For 2015, inclusion was based on probe-based real-time duplex PCR for detection of toxin genes tcdA and tcdB according to de Boer et al. 16 The method was locally modified and verified for use with eSwab samples at 1:10 dilution instead of a direct assay from faeces. Characteristic result curves with C t values ,40 were interpreted as positive. The study included individuals demonstrating a positive test, who were at least 18 years of age, fulfilling a HCF-CDI diagnosis, which was defined as symptom onset .48 h after admission or inpatient care within 4 weeks before onset. The latter definition is based on the recommendations by McDonald et al. 17 Patients with a CDI history during the previous 8 weeks (recurrent CDI) were excluded.
Data collection
Medical records of patients fulfilling the inclusion criteria were reviewed by two infectious diseases resident physicians. The patient characteristics recorded were age, sex, number of days spent in hospital in the past 30 days and the past year, and specific risk factors for CDI (inflammatory bowel disease; haematological malignancies; diabetes; chronic renal failure; treatment with corticosteroids; treatment with proton pump inhibitors). For antibiotics, name, Anatomic Therapeutic Chemical classification, administration route and number of DDDs given during the 30 days prior to the positive diagnostic test were recorded. The choice of a 30 day span for previous hospitalization was deemed most relevant to monitor based on consideration of two studies 18, 19 in which CDI risk was found to decrease substantially 1 month after antibiotic treatment. The number of days between the last dose of antibiotics (0-30) and the positive toxin/PCR test was registered (measured as the date the sample was received and registered at the microbiology laboratory). ICU care and date of death were also recorded, when applicable. We also determined the two hospitals' total antibiotic sales in DDD/year using data from the hospital pharmacy (ASP hospital) and the Swedish eHealth agency (non-ASP hospital). Data on the total number of admissions at the hospitals were collected using IBM Cognos (IBM, Armonk, NY, USA). Data on ribotype and susceptibility testing of a small fraction of our isolates were provided by the Public Health Agency of Sweden. Microbiological laboratories in Sweden have collected isolates for typing and susceptibility testing 2 weeks every year (1 week during spring and one during autumn) since 2009.
Attributing an HCF-CDI case to particular antibiotics HCF-CDI cases were attributed to the antibiotic(s) given during the last 30 days before the positive test, weighted based on the number of DDDs given of each antibiotic. For instance, if a patient had received four DDDs of antibiotic A and four DDDs of antibiotic B, the case is attributed equally to antibiotics A and B (0.5 attributable case each).
Statistical methods
Results are presented as the mean and standard deviation for quantitative variables that are approximately normally distributed, median and IQR for non-normally distributed quantitative variables, and numbers and percentages for categorical variables. For single comparisons between only two groups, the Mann-Whitney U-test was used for quantitative variables and Fisher's exact test was used for categorical variables. Statistical significance of differences between groups in the patient characteristics were calculated using the non-parametric Kruskal-Wallis test for quantitative variables, as none of these variables passed the D'Agostino and Pearson normality test for all groups. The v 2 test was used for categorical variables. If a statistically significant difference between groups was detected, follow-up post-hoc tests were performed. To limit the number of analyses, only five follow-up tests were performed: comparisons between hospitals in the same year (three analyses) and comparisons between all years at the same hospital (two analyses). For the former, the Mann-Whitney Utest was used for quantitative variables and Fisher's exact test was used for categorical variables. For the latter, as there were still multiple groups, the Kruskal-Wallis test was used for quantitative variables and the v 2 test was used for categorical variables. Post-hoc tests were corrected using the Clostridioides difficile incidence and cephalosporin usage JAC Bonferroni method; as there were five follow-up tests, the cut-off for statistical significance was set to a " 0.01 for these tests.
GraphPad Prism version 7 (GraphPad Software, San Diego, CA, USA) was used for statistical analyses and for producing graphs.
Results
At the ASP hospital, the use of cephalosporins decreased considerably during the study years from 19 343 DDDs (2007) In relation to the decrease in cephalosporin use at the ASP hospital, we also noted an expected increase in the use of other antibiotics. Similar but less pronounced changes were noted at the non-ASP hospital. Among the iv alternatives to cephalosporins, the largest increase was seen in piperacillin/tazobactam ( Table 1) .
The numbers of HCF-CDI cases that met the inclusion criteria (in total n " 398) at the ASP hospital were n " 73 (2007), n " 48 (2012, including 9 equivocal cases) and n " 35 (2015, including 6 equivocal cases) compared with n " 85 (2007), n " 68 (2012) and n " 89 (2015) at the non-ASP hospital. Table 2 shows patient characteristics for both hospitals and all years. Follow-up post hoc tests for significant differences between groups, as described in the Patients and methods section, showed a significant increase in prevalence of renal insufficiency between years at the ASP hospital (P " 0.008) and a significant difference between years for the number of prescribed drugs at admission at the non-ASP hospital (P " 0.003) and between hospitals in 2007 (P " 0.004). In addition, there were differences in the time of disease onset in relation to antibiotic therapy, with disease onset occurring earlier at the non-ASP hospital. Post-hoc analysis showed a significant difference between hospitals for disease onset during antibiotic therapy in 2012 (P " 0.008) and 2015 (P , 0.0001), as well as a significant difference between hospitals for disease onset without known antibiotic therapy in 2015 (P " 0.002) ( Table 2) . Although there was a significant difference in the frequency of vancomycin treatment with all groups compared, there were no significant differences between hospitals or between years within a hospital in the post hoc analysis.
To compare the incidence of HCF-CDI before and after the ASP we calculated the cases into the comparable unit HCF-CDI/1000 hospital admissions. At the ASP hospital, the number of HCF-CDI/ 1000 hospital admissions decreased significantly from 2. When comparing the two hospitals regarding the number of HCF-CDI/1000 hospital admissions, there was no significant difference between hospitals in 2007 (P " 0.70) or 2012 (P " 0.46), but in 2015 there was a statistically significant lower rate of HCF-CDI/ 1000 hospital admissions at the ASP hospital than at the non-ASP hospital (P " 0.0002).
When we analysed the individual HCF-CDI cases and attributed them to the antibiotics given during the last 30 days before the positive test, we found that use of iv cephalosporins could be linked to a substantial portion of the HCF-CDI in both hospitals in 2007: ASP hospital 0.72 HCF-CDI cases/1000 hospital admissions; non-ASP hospital 0.58 HCF-CDI cases/1000 hospital admissions. Most of these were attributed to cefuroxime: ASP hospital 0.68/1000 hospital admissions; non-ASP hospital 0.58/1000 hospital admissions. A high proportion of cases due to iv cephalosporins continued at the non-ASP hospital in 2012 (0.51/1000 hospital admissions) and 2015 (0.79/1000 hospital admissions). At the ASP hospital, cases attributed to iv cephalosporins decreased markedly, as expected, i.e. in 2012, 0.04/ 1000 hospital admissions, and 2015, 0.05/1000 hospital admissions (see Figure 2) .
Despite the fact that usage of several antibiotics increased markedly at the ASP hospital in 2012 and 2015, none of them showed a corresponding increase as attributed agents for HCF-CDI in our analysis (see Figure 3) . For comprehensive data, see Table  S1 , available as Supplementary data at JAC Online).
To estimate the propensity for different antibiotics to cause HCF-CDI at our hospitals, we combined the attributed cases from both hospitals in all three years and divided by the total amount A selection of antibiotics with high consumption (total sales at both hospitals in all years .10 000 DDD) that had a marked change in use (.60% increase or decrease compared with 2007 levels at any of the hospitals in any year) are included in the table. For a complete list, see Table S1 .
Karp et al. Clostridioides difficile incidence and cephalosporin usage JAC consumed in DDD of each antibiotic. In this summarized material, cefotaxime has the highest number of attributed cases in relation to antibiotic sales, followed by cefuroxime, clindamycin, ceftibuten and levofloxacin (see Figure 4) . To determine whether the change to a PCR-based method at the non-ASP hospital in October 2013 had an impact on the number of HCF-CDI cases in 2015, we reviewed the total number of tests and the proportion of positive tests 21 months prior to and after the change. Before the change, the total number of tests was 3465 with 13% positive, compared with 3946 tests with 11% positive after, thus indicating no rise in sensitivity. A similar analysis for the 11 months before and after the change from the Premier test to the Vidas test at the ASP hospital showed a decrease in the proportion of positive tests from 14.0% (163 of 1163 tests) to 9.5% (113 of 1194 tests), P " 0.0007. It should be noted that the change was made in February 2008, during the same time that the ASP was being implemented.
The data from the Public Health Agency of Sweden (a random selection of isolates collected for ribotyping 2009-17; n " 77 at the ASP hospital, n " 72 at the non-ASP hospital) showed that the same ribotypes are most common at both hospitals (014, 078, 002, 001 and 023 in order of declining frequency). These are also among the most common ribotypes in Sweden, in general. 20 Susceptibility testing from the samples showed low levels of resistance to erythromycin, moxifloxacin and clindamycin.
Discussion
Our main finding is that a reduction in cephalosporin sales at a secondary care hospital in western Sweden was followed by a significant decrease in the incidence rate of HCF-CDI. The hypothesis of a causal relationship was strengthened by the finding of an unchanged HCF-CDI rate at a similar hospital in the same region, where changes in antibiotic usage were much less pronounced. Our attribution of cases showed that a large proportion was linked to cephalosporin treatment prior to disease onset. By examining 2 years (2012 and 2015) after, as well as 1 year (2007) before the ASP, we can conclude that the changes seem to be sustainable. As a reference point, the CDI incidence (not restricted to healthcare facility-associated infections) on a national level decreased by 20% during the years 2007-15 and the incidence in our region was below the national average. 20 We believe that there are several strengths in our study design. We compared two similar hospitals regarding size and function, antibiotic resistance rates, administrative region, infection control organization and isolation facilities, in a setting of low antibiotic use and high CDI incidence. An investigation with comparable similarities has, to our knowledge, not been done before. Another strength was the collection of both aggregated data for HCF-CDI and antibiotic sales, as well as data on an individual level from meticulous examination of medical records.
An interesting incidental finding is that the onset of HCF-CDI occurred more often during antibiotic treatment at the non-ASP hospital than at the ASP hospital in 2012 (69.1% versus 43.8%, P " 0.008) and this difference was even more pronounced in 2015 (76.4% versus 34.3%, P , 0.0001). Before the ASP (2007), there was no difference between the hospitals in this regard. Thus, treatment with cephalosporins not only resulted in a higher frequency of HCF-CDI, but our results suggest that the onset of infection occurred earlier after initiation of antibiotic treatment at a hospital with high cephalosporin use. Another result that points in that direction is that the number of cases without known antibiotic treatment increased at the ASP hospital (Table 2) . However, this is a finding based on a small number of patients, and other risk factors besides treatment with antibiotics are also important for developing CDI. Therefore, it is important to keep in mind that in some cases of CDI, antibiotic treatment could be a circumstantial factor rather than the main causative factor. The marked decrease in HCF-CDI at the ASP hospital is in line with results from earlier studies. A recent meta-analysis showed that implementation of ASPs decreased the incidence of CDI by 32%, in general. 13 Included studies came from different settings, i.e. small specific wards, bigger units and large hospitals. [21] [22] [23] Another study, more specifically investigating the use of piperacillin/tazobactam in preference over cefotaxime, saw a reduction of HCF-CDI by 52%, 24 which is well in line with our results. A weakness of our study is that three different laboratory tests were used. These vary in sensitivity and specificity, which likely affects the measured incidence to some degree. In addition, in the ASP hospital the use of an EIA-only diagnostic procedure could exaggerate the total CDI rate and there is a small possibility that a drop in actual disease could be masked by an increase in false positive results, which occurred at the same time. Although the proportion of positive results significantly declined at the ASP hospital after the change in EIA method, the implementation of the ASP occurred at the same time, making it difficult to determine the relative importance of these two factors. However, although earlier studies have shown comparability between the two EIA techniques, 15 we explored the scenario that allowed for the highest post-intervention calculations of HCF-CDI at the ASP hospital, including patients with equivocal VIDAS test results who were treated for clinically suspected HCF-CDI and/or when other explanations for diarrhoeal symptoms were lacking. Concerning the test change at the non-ASP hospital, we investigated how the introduction of the PCR test affected the proportion of positive tests: there was actually an overall decrease in positivity.
The larger proportion of patients at the non-ASP hospital who fell ill in close relation to antibiotic treatment, as well as the strong association with cephalosporin treatment in the attribution of cases, provides support for the notion that the declining incidence at the ASP hospital was a real effect of reductions in cephalosporin use.
Another weakness in our study is the low number of isolates that were ribotyped and susceptibility tested. The impact of ASPs in different settings might covariate with ribotype diversity and susceptibility patterns. However, the few strains tested from our hospitals were similar in terms of ribotype and susceptibility patterns. Further, a contributing factor to differing HCF-CDI incidence Clostridioides difficile incidence and cephalosporin usage JAC could be facility design. The hospitals in our study are similar when it comes to number of beds, but new facilities with a higher proportion of single-bed rooms were introduced at the ASP hospital in 2010. These changes might have impacted the incidence of HCF-CDI by making it easier to avoid hospital spread and colonization with C. difficile. 25 Newly built facilities, at least initially, provide an environment free from C. difficile spores, which may be present in older buildings. The strong connection to cephalosporin use in attributed cases also makes it unlikely that a lower colonization rate could explain the main finding of the results. If this was the case, a decrease in all HCF-CDI cases would be expected, regardless of antibiotics given. Nonetheless, it cannot be ruled out that a higher proportion of single-bed rooms may have amplified the effect of the ASP in this study.
Our method to attribute the CDI cases to the antibiotics given 30 days before the positive test can be questioned. We chose to attribute the cases equally without considering the different antibiotics' abilities to cause CDI. This makes it possible, in some cases, for antibiotics to be 'guilty by association'. If a patient had a short treatment with cefotaxime followed by a longer treatment by benzylpenicillin, the largest proportion of the CDI case would be attributed to the penicillin. With current knowledge of different antibiotics' tendencies to cause CDI, it might be more reasonable to believe that the CDI case was caused mainly by cefotaxime. Thus, our method of attributing cases to antibiotics might underestimate the true risk increase by cephalosporins. We conclude, however, that our method results in risk estimates for different antibiotics that are in line with previous studies. 6 Some researchers 10 have questioned the relationship between cephalosporin use and CDI incidence. Concern is raised as to whether it is possible to decrease CDI incidence with an ASP targeting a single class of antibiotics, as there may just be substitution with other antibiotics that have a similar risk of CDI. Our results do not support this idea, at least when it comes to HCF-CDI. Although the decrease in cephalosporin consumption in our study was accompanied by an increase in consumption of the b-lactam/ b-lactamase inhibitor piperacillin/tazobactam, the number of HCF-CDI cases linked to this agent increased only moderately. This finding may be due to an effect of piperacillin/tazobactam on C. difficile, preventing colonization. 26, 27 Wilcox et al. 10 also point out that different cephalosporins have different impacts on CDI incidence, and thus it is imprecise to talk about how cephalosporins as a class can affect CDI incidence. Our results could further strengthen that assumption when looking at the impact of cefuroxime versus cefotaxime on HCF-CDI incidence. Cephalosporin use at the non-ASP hospital also decreased during the years studied. At first this resulted in a decrease in HCF-CDI (2012), which was followed by an increase (2015), although these changes were not statistically significant. In addition, there were more cases attributed to cefotaxime in 2015 than cases attributed to cefuroxime in 2007, despite a reduction in use of more than a third of the iv cephalosporin of choice at the non-ASP hospital (Table S1 ). Finally, when we pooled all attributed cases for all years at both hospitals, the impact of cefotaxime on HCF-CDI was remarkable compared with all other antibiotics including cefuroxime (Figure 4) . Cefotaxime is eliminated to the bowel in active form to a greater extent than cefuroxime, and this may partially explain the different impacts of these cephalosporins on HCF-CDI. 28, 29 The effort to minimize HCF-CDI is multifaceted, with antibiotic choice as one of several key factors. Our results show that an ASP targeting cephalosporins can have a major impact on HCF-CDI incidence in a setting with low antibiotic use and antimicrobial resistance, but high HCF-CDI incidence. We suggest that minimizing the use of cephalosporins in general, and the third-generation cephalosporin cefotaxime in particular, is an effective way to lower HCF-CDI incidence. As clinicians, it is our responsibility to make antibiotic therapy choices that reduce exposure to harm in our patients, even if seen in a more collective way and over time.
